Moderna (MRNA) Competitors $26.56 +1.32 (+5.23%) Closing price 04:00 PM EasternExtended Trading$26.52 -0.04 (-0.17%) As of 06:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock MRNA vs. CRSP, CVAC, HOOD, NVAX, OCGN, TSLA, JNJ, MRK, PFE, and ONCShould you be buying Moderna stock or one of its competitors? The main competitors of Moderna include CRISPR Therapeutics (CRSP), CureVac (CVAC), Robinhood Markets (HOOD), Novavax (NVAX), Ocugen (OCGN), Tesla (TSLA), Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK), Pfizer (PFE), and BeOne Medicines (ONC). Moderna vs. Its Competitors CRISPR Therapeutics CureVac Robinhood Markets Novavax Ocugen Tesla Johnson & Johnson Merck & Co., Inc. Pfizer BeOne Medicines Moderna (NASDAQ:MRNA) and CRISPR Therapeutics (NASDAQ:CRSP) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, valuation, dividends, earnings, institutional ownership, analyst recommendations, media sentiment and risk. Is MRNA or CRSP more profitable? Moderna has a net margin of -94.31% compared to CRISPR Therapeutics' net margin of -1,229.43%. CRISPR Therapeutics' return on equity of -20.05% beat Moderna's return on equity.Company Net Margins Return on Equity Return on Assets Moderna-94.31% -25.96% -20.09% CRISPR Therapeutics -1,229.43%-20.05%-17.09% Which has more risk and volatility, MRNA or CRSP? Moderna has a beta of 1.93, suggesting that its share price is 93% more volatile than the S&P 500. Comparatively, CRISPR Therapeutics has a beta of 1.81, suggesting that its share price is 81% more volatile than the S&P 500. Which has better valuation and earnings, MRNA or CRSP? CRISPR Therapeutics has lower revenue, but higher earnings than Moderna. CRISPR Therapeutics is trading at a lower price-to-earnings ratio than Moderna, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioModerna$3.06B3.38-$3.56B-$7.53-3.53CRISPR Therapeutics$35M161.37-$366.25M-$5.43-11.44 Does the media prefer MRNA or CRSP? In the previous week, Moderna and Moderna both had 17 articles in the media. CRISPR Therapeutics' average media sentiment score of 0.69 beat Moderna's score of 0.63 indicating that CRISPR Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Moderna 6 Very Positive mention(s) 4 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive CRISPR Therapeutics 5 Very Positive mention(s) 3 Positive mention(s) 5 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals and insiders have more ownership in MRNA or CRSP? 75.3% of Moderna shares are owned by institutional investors. Comparatively, 69.2% of CRISPR Therapeutics shares are owned by institutional investors. 11.0% of Moderna shares are owned by insiders. Comparatively, 4.3% of CRISPR Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Do analysts recommend MRNA or CRSP? Moderna currently has a consensus target price of $41.81, indicating a potential upside of 57.43%. CRISPR Therapeutics has a consensus target price of $71.50, indicating a potential upside of 15.14%. Given Moderna's higher probable upside, equities research analysts clearly believe Moderna is more favorable than CRISPR Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Moderna 4 Sell rating(s) 14 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.05CRISPR Therapeutics 1 Sell rating(s) 7 Hold rating(s) 10 Buy rating(s) 0 Strong Buy rating(s) 2.50 SummaryModerna and CRISPR Therapeutics tied by winning 8 of the 16 factors compared between the two stocks. Get Moderna News Delivered to You Automatically Sign up to receive the latest news and ratings for MRNA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MRNA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MRNA vs. The Competition Export to ExcelMetricModernaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$10.33B$3.16B$5.79B$10.49BDividend YieldN/A2.36%5.61%4.57%P/E Ratio-3.5321.17348.8926.87Price / Sales3.38411.81522.55164.30Price / CashN/A44.8326.0131.15Price / Book0.949.8315.536.50Net Income-$3.56B-$52.82M$3.29B$271.42M7 Day Performance11.22%3.47%200.87%3.69%1 Month Performance-2.06%5.35%184.38%8.07%1 Year Performance-59.57%13.26%325.51%29.65% Moderna Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MRNAModerna4.4639 of 5 stars$26.56+5.2%$41.81+57.4%-61.6%$10.33B$3.06B-3.535,800CRSPCRISPR Therapeutics2.9966 of 5 stars$57.14+1.6%$71.60+25.3%+29.3%$5.19B$37.31M-10.51460CVACCureVac4.0844 of 5 stars$5.35+0.1%$6.83+27.8%+65.6%$1.20B$579.18M5.57880Positive NewsHOODRobinhood Markets3.7656 of 5 stars$115.13+0.1%$101.88-11.5%+449.0%$102.38B$2.95B58.482,300Trending NewsNVAXNovavax4.1957 of 5 stars$7.91-0.9%$14.29+80.7%-32.5%$1.29B$1.08B3.471,990OCGNOcugen1.6037 of 5 stars$1.17+8.9%$6.00+415.0%+20.7%$340.53M$4.05M-5.8280Positive NewsAnalyst ForecastGap UpHigh Trading VolumeTSLATesla4.343 of 5 stars$416.86+5.3%$303.00-27.3%+78.8%$1.35T$97.69B241.44125,665Trending NewsAnalyst UpgradeJNJJohnson & Johnson4.7355 of 5 stars$177.10-0.5%$176.29-0.5%+7.2%$426.92B$90.63B18.96138,100Positive NewsAnalyst ForecastMRKMerck & Co., Inc.4.9993 of 5 stars$81.32-0.8%$107.44+32.1%-30.5%$203.14B$64.17B12.5375,000Positive NewsPFEPfizer4.9859 of 5 stars$23.80-0.3%$28.12+18.2%-18.3%$135.23B$63.63B12.6581,000Trending NewsAnalyst UpgradeOptions VolumeONCBeOne Medicines1.8395 of 5 stars$331.43+2.2%$330.89-0.2%N/A$36.32B$3.81B-191.5811,000 Related Companies and Tools Related Companies CRISPR Therapeutics Alternatives CureVac Alternatives Robinhood Markets Alternatives Novavax Alternatives Ocugen Alternatives Tesla Alternatives Johnson & Johnson Alternatives Merck & Co., Inc. Alternatives Pfizer Alternatives BeOne Medicines Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MRNA) was last updated on 9/22/2025 by MarketBeat.com Staff From Our PartnersNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredPrepare for the “Mar-a-Lago Accord” Money ShockWhy Are Wall Street Insiders Moving Their Money to This ONE Asset? Something far more consequential for you...Stansberry Research | SponsoredForget AI Stocks — This Device Will REPLACE the MicrochipWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Moderna, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Moderna With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
